ERBB2 Exon 20 Insertion is an inclusion criterion in 9 clinical trials for non-small cell lung carcinoma, of which 8 are open and 1 is closed. Of the trials that contain ERBB2 Exon 20 Insertion and non-small cell lung carcinoma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 7 are phase 2 (6 open) [5].

Ado-trastuzumab emtansine and fam-trastuzumab deruxtecan have evidence of efficacy in patients with ERBB2 Exon 20 Insertion in non-small cell lung carcinoma [5].

ERBB2 Exon 20 Insertion is an inclusion criterion in 8 clinical trials for malignant solid tumor, of which 8 are open and 0 are closed. Of the trials that contain ERBB2 Exon 20 Insertion and malignant solid tumor as inclusion criteria, 1 is phase 1 (1 open), 2 are phase 1/phase 2 (2 open), and 5 are phase 2 (5 open) [5].

ERBB2 Exon 20 Insertion is an inclusion criterion in 3 clinical trials for breast carcinoma, of which 3 are open and 0 are closed. Of the trials that contain ERBB2 Exon 20 Insertion and breast carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 2 are phase 2 (2 open) [5].

ERBB2 Exon 20 Insertion is an inclusion criterion in 1 clinical trial for adenocarcinoma of the gastroesophageal junction, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 Exon 20 Insertion and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 1 is phase 2 (1 open) [5].

ERBB2 Exon 20 Insertion is an inclusion criterion in 1 clinical trial for biliary tract carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 Exon 20 Insertion and biliary tract carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

ERBB2 Exon 20 Insertion is an inclusion criterion in 1 clinical trial for breast adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 Exon 20 Insertion and breast adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

ERBB2 Exon 20 Insertion is an inclusion criterion in 1 clinical trial for cervical carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 Exon 20 Insertion and cervical carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

ERBB2 Exon 20 Insertion is an inclusion criterion in 1 clinical trial for colorectal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 Exon 20 Insertion and colorectal carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

ERBB2 Exon 20 Insertion is an inclusion criterion in 1 clinical trial for diffuse midline glioma, H3 K27M-mutant, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 Exon 20 Insertion and diffuse midline glioma, H3 K27M-mutant as inclusion criteria, 1 is phase 2 (1 open) [5].

ERBB2 Exon 20 Insertion is an inclusion criterion in 1 clinical trial for gastric adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 Exon 20 Insertion and gastric adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

ERBB2 Exon 20 Insertion is an inclusion criterion in 1 clinical trial for gastric carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 Exon 20 Insertion and gastric carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

ERBB2 Exon 20 Insertion is an inclusion criterion in 1 clinical trial for glioblastoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 Exon 20 Insertion and glioblastoma as inclusion criteria, 1 is phase 2 (1 open) [5].

ERBB2 Exon 20 Insertion is an inclusion criterion in 1 clinical trial for malignant uterine neoplasm, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 Exon 20 Insertion and malignant uterine neoplasm as inclusion criteria, 1 is phase 2 (1 open) [5].

ERBB2 Exon 20 Insertion is an inclusion criterion in 1 clinical trial for non-squamous non-small cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 Exon 20 Insertion and non-squamous non-small cell lung carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

ERBB2 Exon 20 Insertion is an inclusion criterion in 1 clinical trial for urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 Exon 20 Insertion and urothelial carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

ERBB2 Exon 20 Insertion is an inclusion criterion in 1 clinical trial for WHO grade III glioma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 Exon 20 Insertion and WHO grade III glioma as inclusion criteria, 1 is phase 2 (1 open) [5].